Blood centres that fail quality checks may face testing curbs

politics logo
The propositions follow reports of a number of cases including contaminated or mismatched blood transfusions in kids. (Pexel)
Summary

The federal government might make involvement of approximately 5,000 signed up blood centres in India in external quality checks lawfully binding under the Drugs Rules, 1945.

New Delhi: Blood centres throughout India that stop working obligatory quality audits might quickly be disallowed from performing regular screening up until they recognize what failed and repair it, according to the propositions sent

to the leading drug-regulatory advisory body.

If authorized, the proposition by a sub-committee of the Drugs Consultative Committee will make involvement of approximately 5,000 signed up blood centres in external quality checks lawfully binding under the Drugs Rules, 1945, according to 2 individuals and a file seen by Mint

.

The propositions follow reports of a number of cases including contaminated or mismatched blood transfusions in kids. In Jharkhand, 5 kids with thalassemia, aged 5 to 7, supposedly contracted HIV after getting transfusions at Chaibasa Sadar Hospital.

India gathered 14.6 million systems of blood in 2024-25, up 15%year-on-year, the Union ministry of health and household well-being informed Parliament in August 2025. Around 70% of this supply originated from voluntary, non-remunerated donors, demanding a robust quality management system at the blood centres.

More stringent oversight

At present, involvement of certified blood centres in the External Quality Assessment Schemes (EQAS) stays voluntary, and lacunae in their screening and collection procedures bring no genuine legal repercussions.

Internationally, regulative structures in nations such as the United States, the UK, and throughout the European Union mandate routine efficiency screening for blood banks, connecting lab accreditation and licensing straight to external quality efficiency.

The World Health Organization likewise advises required EQAS involvement as a core pillar of nationwide haemovigilance and transfusion security systems.

Under the EQAS, an independent referral centre sends out blind efficiency samples to a certified blood centre, which should evaluate them to confirm its diagnostic precision and quality management system.

The suggestions were prepared by a five-member sub-committee chaired by Rajasthan drugs controller Ajay Phatak, made up by the Central Drugs Standard Control Organisation (CDSCO). The panel consisted of state drugs controllers from Jharkhand and Punjab, along with agents from the National Blood Transfusion Council (NBTC) and the CDSCO blood centre department.

Blood centres are presently based on analysis by state federal government regulators, however their compulsory involvement in the EQAS would likewise position them under higher Central federal government tracking.

Under the proposed system, signed up blood centres will go through regular efficiency screening within a structured January-to-December yearly calendar(with the Indian Red Cross Society design utilizing 3 screening cycles each year at an expense of 5,000 as a criteria ).

They will require to check dispersed efficiency samples– covering blood grouping, cross-matching, haemoglobin, HIV, Hepatitis B, Hepatitis C, syphilis, and malaria– on the day right away after invoice.

Blind referral samples will be dispersed throughout 5 peak nationwide EQAS centres– Christian Medical College Vellore, Indian Red Cross Society Mumbai, Santokba Durlabhji Memorial Hospital Jaipur, Post Graduate Institute of Medical Education and Research Chandigarh, and Gauhati Medical College Guwahati– while state drugs controllers will get all audit reports straight to impose compliance and conduct regulative evaluations.

“If a blood centre fails to meet the required proficiency standards during a cycle, it cannot continue routine testing without review. The centre will be mandated to perform a formal root cause analysis (RCA) and implement a corrective and preventive action (CAPA) protocol to rectify testing errors,” showed the minutes of the sub-committee meeting.

Proposed punishments for non-compliant facilities include statutory fines, suspension of testing privileges, and disciplinary action by state regulators.

Mint‘s queries emailed to the spokesperson of the health ministry, CDSCO, and Rajasthan drugs controller remained unanswered.

Welcome move

Blood transfusion safety is not limited to screening donated blood for infections; it requires strict quality control at every stage, from donor selection and blood collection to testing, storage, compatibility checks and administration, said Vijay Kumar Sharma, consultant, internal medicine, Regency Healthcare.

“Obligatory external quality evaluations are vital to determine screening errors before they jeopardize client security. Blood centres should preserve confirmed screening treatments, trained workers, correct paperwork and constant tracking. Any failure needs to set off instant examination and restorative action,” he included.

article-index-22″ data-slot=”22″>

The proposition has actually been sent to the Drugs Consultative Committee, a leading statutory advisory panel of main and state drug regulators, which will quickly take a last get in touch with it, according to the 2 individuals pointed out on top.

article-index-23″ data-slot=”23″>

Before alerting the modifications, the NBTC will establish a phased shift strategy and functional standards, together with sample rates standards and non-compliance requirements, to avoid blood supply disturbances. Any draft guidelines in this regard will go to state blood transfusion councils for feedback.

article-index-24″ data-slot=”24″>

“Blood transfusion represent the significant source of viral transmission. Untried or semi-tested blood transfusion is still typical, specifically in peripheries. This relocation can assist, although it can not totally guarantee that the centres follow the SOPs and standards,” stated Ravneet Kaur, basic supervisor and laboratory head, Agilus Diagnostics Lab, Fortis Noida.

About the Author

Priyanka Sharma

Priyanka Sharma is a reporter at Mint, where she covers the Union Ministry of Health and the pharmaceutical market. Her work concentrates on discussing federal government policies and how they affect health care and the medication market in India. With 12 years of experience in journalism, she has actually developed a track record for offering clear and sincere news on essential health subjects that impact the whole nation.<
<>
> Her academic background consists of a journalism degree from the distinguished Indian Institute of Mass Communication (IIMC) and specialized training in public health from the general public Health Foundation of India. Before her present function at Mint, Priyanka dealt with India Today, The Pioneer, and ANI. She likewise worked as a lead specialist for the National Health Authority, which offered her direct understanding of how the federal government handles massive health programs.<
<>
> Priyanka is based in New Delhi and is a passionate tourist who likes checking out the mountains. She has an excellent interest in local flavours, especially South Indian food.


Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND

Subscribe to get the latest posts sent to your email.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Captcha verification failed!
CAPTCHA user score failed. Please contact us!

spot_imgspot_imgspot_imgspot_img